No mechanistic data are available for PrCa, but patients with CHEK2 mutations are among those showing a high response rate to treatment with the poly-ADP ribose polymerase inhibitor Olaparib when cancers were no longer responding to standard treatments [41]. This evidence concerns the gene CHEK2 and cancer.